Overall, emerging evidence shows that Ang-(1-7) is protective for both cardiovascular and metabolic outcomes in animal models, and thus may provide an alternate approach to target the RAS in obesity hypertension without eliciting the adverse side effects seen with traditional RAS inhibitors. This evidence concerns the gene ANG and obesity due to melanocortin 4 receptor deficiency.